Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice

Journal of Clinical Investigation

Volumn 114, Issue 6, 2004, Pages 784-794

  Kobayashi, Takuya ^a   Tahara, Yoshio ^a   Matsumoto, Mayumi ^a   Iguchi, Masako ^a   Sano, Hideto ^a   Murayama, Toshinori ^a   Arai, Hidenori ^a   Oida, Hiroji ^b   Yurugi Kobayashi, Takami ^a   Yamashita, Jun K ^a   Katagiri, Hiroyuki ^c   Majima, Masataka ^c   Yokode, Masayuki ^a   Kita, Toru ^a   Narumiya, Shuh ^a  

^a KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CD31 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; LIPOPROTEIN SYNTHESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD31; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; EPOPROSTENOL; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MICE; MICE, KNOCKOUT; PLATELET AGGREGATION; RECEPTORS, EPOPROSTENOL; RECEPTORS, THROMBOXANE; THROMBOXANE A2;

EID: 9644272529     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200421446     Document Type: Article

References (69)

1. Ross, R. 1999. Atherosclerosis is an inflammatory disease. Am. Heart. J. 138:S419-S420.
2. FitzGerald, G.A., Smith, B., Pedersen, A.K., and Brash, A.R. 1984. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. 310:1065-1068.
3. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D.J. 2000. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 102:840-845.
4. Plump, A.S., et al. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
5. Zhang, S.H., Reddick, R.L., Piedrahita, J.A., and Maeda, N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
6. Ishibashi, S., et al. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:883-893.
7. Cyrus, T., et al. 2002. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 106:1282-1287.
8. Cayatte, A.J., et al. 2000. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:1724-1728.
9. Vane, J.R., Bakhle, Y.S., and Botting, R.M. 1998. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol. 38:97-120.
10. McAdam, B.F., et al. 1999. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 96:272-277.
11. Topper, J.N., Cai, J., Falb, D., and Gimbrone, M.A., Jr. 1996. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U. S. A. 93:10417-10422.
12. Foeldvari, I. 2002. A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen [letter]. Clin. Exp. Rheumatol. 20:874.
13. Mukherjee, D., Nissen, S.E., and Topol, E.J. 2001. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:954-959.
14. Rott, D., et al. 2003. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. Coll. Cardiol. 41:1812-1819.
15. Burleigh, M.E., et al. 2002. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 105:1816-1823.
16. Pratico, D., Tillmann, C., Zhang, Z.B., Li, H., and FitzGerald, G.A. 2001. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98:3358-3363.
17. Belton, O.A., Duffy, A., Toomey, S., and Fitzgerald, D.J. 2003. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation. 108:3017-3023.
18. Narumiya, S., Sugimoto, Y., and Ushikubi, F. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:1193-1226.
19. 2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol. 4:694-701.
20. Murata, T., et al. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 388:678-682.
21. 2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol. 61:1153-1160.
22. Fujino, T., et al. 2002. Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells. Br. J. Pharmacol. 136:530-539.
23. Hoshikwa, Y., et al. 2001. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care. Med. 164:314-318.
24. 2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation. 104:2210-2215.
25. Takahashi, Y., et al. 2002. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol. 137:315-322.
26. 2 in airway remodeling induced by repeated allergen challenge in mice. Am. J. Respir. Cell Mol. Biol. 29:314-320.
27. 2 regulates the neural emergency system through release of calcitonin gene related peptide. Gut. 52:1242-1249.
28. 2 regulates vascular tone via its inhibitory effect on the expression of inducible nitric oxide synthase. Circulation. 108:2381-2386.
29. Katagiri, H., et al. 2004. Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice. Hepatology. 39:139-150.
30. Rosenfeld, M.E., et al. 2000. Advanced atherosclerotic lesions in the innominate artery of the apoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 20:2587-2592.
31. 2. Science. 296:539-541.
32. Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L., and Ross, R. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-140.
33. Pratico, D., Cyrus, T., Li, H., and FitzGerald, G.A. 2000. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood. 96:3823-3826.
34. Libby, P., Schoenbeck, U., Mach, F., Selwyn, A.P., and Ganz, P. 1998. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am. J. Med. 104:14S-18S.
35. Hartung, H.P., Kladetzky, R.G., Melnik, B., and Hennerici, M. 1986. Stimulation of the scavenger receptor on monocytes-macrophages evokes release of arachidonic acid metabolites and reduced oxygen species. Lab. Invest. 55:209-216.
36. Fitzgerald, D.J., Roy, L., Catella, P., and FitzGerald, G.A. 1986. Platelet activation in unstable coronary disease. N. Engl. J. Med. 315:983-989.
37. 2-dependent plaque instability. Circulation. 104:921-927.
38. Cipollone, F., et al. 2003. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 108:1070-1077.
39. Kitahara, M., et al. 2001. Prostacyclin inhibits the production of MMP-9 induced by phorbol ester through protein kinase A activation, but does not affect the production of MMP-2 in human cultured mesangial cells. Kidney Blood Press. Res. 24:18-26.
40. Schermuly, R. T., et al. 2004. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94:1101-1108.
41. Trip, M.D., Cats, V.M., van Capelle, F.J., and Vreeken, J. 1990. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. 322:1549-1554.
42. van Zanten, G.H., et al. 1994. Increased platelet deposition on atherosclerotic coronary arteries. J. Clin. Invest. 93:615-632.
43. Broijersen, A., Hamsten, A., Eriksson, M., Angelin, B., and Hjemdahl, P. 1998. Platelet activity in vivo in hyperlipoproteinemia-importance of combined hyperlipidemia. Thromb. Haemost. 79:268-275.
44. Broijersen, A., Karpe, F., Hamsten, A., Goodall, A.H., and Hjemdahl, P. 1998. Alimentary lipemia enhances the membrane expression of platelet P-selectin without affecting other markers of platelet activation. Atherosclerosis. 137:107-113.
45. Poston, R.N., Haskard, D.O., Coucher, J.R., Gall, N.P., and Johnson-Tidey, R.R. 1992. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am. J. Pathol. 140:665-673.
46. Morisaki, N., et al. 1997. New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis. 131:43-48.
47. Collins, R.G., et al. 2000. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J. Exp. Med. 191:189-194.
48. Springer, T.A. 1990. Adhesion receptors of the immune system. Nature. 346:425-434.
49. Della Bella, S., et al. 2001. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat. 65:73-83.
50. 2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin. Exp. Immunol. 112:464-470.
51. 2 for initiation of platelet-mediated contact sensitivity: dual activation of platelets and vascular endothelial cells. J. Immunol. 166:617-623.
52. Muller, W.A., Weigl, S.A., Deng, X., and Phillips, D.M. 1993. PECAM-1 is required for transendothelial migration of leukocytes. J. Exp. Med. 178:449-460.
53. Duncan, G.S., et al. 1999. Genetic evidence for functional redundancy of platelet/endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1 dependent and PECAM-1-independent functions. J. Immunol. 162:3022-3030.
54. Graesser, D., et al. 2002. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J. Clin. Invest. 109:383-392. doi:10.1172/JCI200213595.
55. Ensminger, S.M., et al. 2002. Platelet-endothelial cell adhesion molecule-1 (CD31) expression on donor endothelial cells attenuates the development of transplant arteriosclerosis. Transplantation. 74:1267-1273.
56. Newman, P.J. 1999. Switched at birth: a new family for PECAM-1. J. Clin. Invest. 103:5-9.
57. Rival, Y., Del Maschio, A., Rabiet, M.J., Dejana, E., and Duperray, A. 1996. Inhibition of platelet endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in endothelial cells by the combined action of TNF-α and IFN-γ. J. Immunol. 157:1233-1241.
58. Ma, H., et al. 2001. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP3. Circulation. 104:1176-1180.
59. Palinski, W., et al. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605-616.
60. Tangirala, R.K., Rubin, E.M., and Palinski, W. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36:2320-2328.
61. Sano, H., et al. 2001. Functional blockade of platelet-derived growth factor receptor-β but not of receptor-α prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation. 103:2955-2960.
62. Murayama, T., et al. 2000. Over expression of low density lipoprotein receptor eliminates apolipoprotein B100-containing lipoproteins from circulation and markedly prevents early atherogenesis in apolipoprotein E-deficient mice. Atherosclerosis. 153:295-302.
63. Nakashima, Y., Raines, E.W., Plump, A.S., Breslow, J.L., and Ross, R. 1998. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18:842-851.
64. Huo, Y., et al. 2003. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 9:61-67.
65. Furchgott, R.F., and Zawadzki, J.V. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:373-376.
66. Poole, J.C.F., Sanders, A.G., and Florey, H.W. 1958. The regeneration of aortic endothelium. J. Pathol. Bacteriol. 75:133-143.
67. Massberg, S., et al. 2003. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J. Exp. Med. 197:41-49
68. Furman, M.I., et al. 1998. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 31:352-358.
69. Michelson, A.D., and Furman, M.I. 1999. Laboratory markers of platelet activation and their clinical significance. Curr. Opin. Hematol. 6:342-348.